Internal Medicine, Medical Oncology · Portland, OR
NPI
1013932854
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
5050 NE Hoyt St Ste 256
Portland, OR, 97213
Phone (503) 239-7767
Groups this clinician bills Medicare through
Medicare paid, 2024
$741K
50,122 services
Medicare patients, 2024
300
Average age 73
Drug cost, 2024
$5.4M
1,496 prescriptions
Company payments, 2024
$0
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robert C Lufkin was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 8,670 times for 12 patients. In total Robert C Lufkin billed 50,122 services in 135 codes, and Medicare paid $741K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-02-19.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 8,670 | 12 | $0.26 | $2,293 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 570 | 19 | $0.24 | $137 |
| 85025 Blood Count | Office | 482 | 185 | $7.57 | $3,651 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 480 | 15 | $0.09 | $43.31 |
| 80053 Clinical Chemistry | Office | 473 | 186 | $10.30 | $4,872 |
| 36415 Venipuncture Blood Collection | Office | 456 | 174 | $8.62 | $3,929 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 270 | 11 | $0.71 | $192 |
| M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 266 | 33 | $71.92 | $19K |
| 99214 Office E&M - Established | Office | 265 | 115 | $92.41 | $24K |
| 83615 Clinical Chemistry | Office | 180 | 75 | $5.92 | $1,066 |
| 99213 Office E&M - Established | Office | 154 | 111 | $66.73 | $10K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 140 | 74 | $11.89 | $1,665 |
| 82784 Immunoassay | Office | 138 | 26 | $9.11 | $1,258 |
| 84153 Clinical Chemistry | Office | 136 | 44 | $18.02 | $2,451 |
| 96413 Chemotherapy Administration | Office | 122 | 41 | $107.53 | $13K |
By year: 2022 $963K for 54,262 services; 2023 $647K for 49,632 services; 2024 $741K for 50,122 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 482 | 185 | $7.57 | $3,651 |
| 80053 Clinical Chemistry | 473 | 186 | $10.30 | $4,872 |
| 36415 Venipuncture Blood Collection | 456 | 174 | $8.62 | $3,929 |
| 83615 Clinical Chemistry | 180 | 75 | $5.92 | $1,066 |
| 82784 Immunoassay | 138 | 26 | $9.11 | $1,258 |
| 84153 Clinical Chemistry | 136 | 44 | $18.02 | $2,451 |
| 84443 Clinical Chemistry | 82 | 25 | $16.46 | $1,350 |
| 83883 Clinical Chemistry | 64 | 15 | $13.33 | $853 |
| 82728 Clinical Chemistry | 33 | 22 | $13.36 | $441 |
| 86300 Immunoassay | 19 | 12 | $20.39 | $387 |
Medicare prescription drug claims, 2024
In 2024, the drug Robert C Lufkin prescribed most often to Medicare patients was Prednisone, with 257 prescriptions and refills. In total Robert C Lufkin wrote 1,496 Medicare prescriptions that cost $5.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 257 | 277 | 48 | $1,096 |
| Abiraterone Acetate Generic | 231 | 231 | 29 | $243K |
| Anastrozole Generic | 59 | 163 | 20 | $781 |
| Dexamethasone Generic | 59 | 66 | 19 | $781 |
| Braftovi Encorafenib | 48 | 48 | Under 11 | $700K |
| Mektovi Binimetinib | 48 | 48 | Under 11 | $610K |
| Xtandi Enzalutamide | 46 | 46 | Under 11 | $490K |
| Letrozole Generic | 42 | 108 | Under 11 | $803 |
| Acyclovir Generic | 36 | 52 | Under 11 | $312 |
| Tamoxifen Citrate Generic | 35 | 80 | Under 11 | $1,578 |
| Gabapentin Generic | 35 | 45 | 11 | $311 |
| Hydroxyurea Generic | 33 | 58 | Under 11 | $599 |
| Jakafi Ruxolitinib Phosphate | 33 | 33 | Under 11 | $584K |
| Lynparza Olaparib | 30 | 30 | Under 11 | $262K |
| Cabometyx Cabozantinib S-Malate | 30 | 30 | Under 11 | $709K |
Brand drugs: 392 claims; generic drugs: 1,104 claims; opioid claims: 30.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid Robert C Lufkin $0 (- in general payments such as food, travel and fees) from 1 company.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.